Dr Thomas Winder, Dr Andrea Sartore-Bianchi and Dr Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences?
Dr Thomas Winder, Dr Andrea Sartore-Bianchi and Dr Yu Sunakawa discuss the Clinical Question: Biomarkers: when to test, what to test and what are the consequences?
Dr Thomas Winder is board certified for haematology and medical oncology. Since January 2020 he has been Head of the Department for Haematology and Oncology at the University Teaching Hospital Feldkirch, Austria. In addition, since 2017 he has been President of the Swiss Tumor Molecular Institute in Zürich Switzerland. Dr Winder’s research focuses on molecular markers to individualize medical treatment of cancer patients. He achieved his expertise in internationally renowned laboratories at University of Southern California, Norris Comprehensive Cancer Center, Los Angeles and University Hospital Zürich, Switzerland. His research activity has been honoured by several national and international awards and high impact publications.
Unmet needs, therapy management, and real-world experience
Make decisions for a young patient during his cancer journey
Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO
Rechallenge vs switching